Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in France / NCT03113552
Recruiting Observational

Prognostic Impact of the Location of Mitral Valve Prolapse on the Long-term Results of Mitral Plasty

NCT03113552 · tracked via the Priya Life Science France tracker
Sponsor
Centre Hospitalier Universitaire, Amiens
Phase
Observational
Started
2013-02-04
Last updated
2023-05-23

Condition(s) studied

Mitral Valve ProlapseMitral Plasty

Study summary

Mitral insufficiency (MI) accounts for 24% of adult valvulopathies and affects 7% of subjects older than 75 years. They are the second leading cause of valvulopathy in Europe. The most common etiology is the associated valvular prolapse. Mitral surgery remains the reference treatment for symptomatic MI. The success of this procedure depends on the mitral valve geometry and the location of the prolapse. The site of the prolapse, whether monovalvular, localized to the posterior or anterior leaflet, or bivalvular, influences the possibilities and probably the long-term results of the plasty.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Patients operated between 1988 and 2011 * Presence of a valvular prolapse diagnosed by echocardiography * Possibility of a complete clinical evaluation at the time of the initial echocardiography Exclusion Criteria: * Ischemic MI (including papillary muscle rupture) * Presence of significant aortic valvulopathy, mitral valvular stenosis or congenital disease * History of cardiac surgery

Primary outcome measure(s)

  • Survival defines as the time between the date of surgery and the death or date of the last news — 6 months

Trial sites (1)

FacilityCityRegionStatus
CHU Amiens Picardie Amiens Picardie Recruiting

More Centre Hospitalier Universitaire, Amiens trials in France

Prevention of Chronic Postsurgical Pain in Chronic Opioid Users: Recruiting
Observance of Continuous Positive Pressure for the Treatment of Obstructive Sleep Apnea Syndrome Active, not recruiting
Effect of a Virtual Reality Program on Patient Comfort in the Surgical Intensive Care Unit Recruiting
Multimodal Quantified Analysis of Facial Movements: Comparison Between Pathological and Control Subjects Recruiting
Access to Kidney Transplant of Obese Patients Beginning Dialysis Recruiting

Other trials for the same condition

STretch and Myocardial Characterization in Arrythmogenic Mitral Valve Prolapse-2 Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT03113552 on ClinicalTrials.gov ↗ ← All trials in France